326-OR: Activity Feature Attenuates Drop in Glucose for Individuals with Type 1 Diabetes Using Omnipod 5 Automated Insulin Delivery System
Authors: TURNER LAUREN V. , SHERR JENNIFER L. , ZAHARIEVA DESSI P. , BARAN JESICA D. , BODE BRUCE W. , BROWN SUE A. , BZDICK SUZAN , MEI CHURCH MEI , HANSEN DAVID W. , KINGMAN RYAN S. , LAFFEL LORI M. , SHAH VIRAL N. , STONE SHERI L. , VIENNEAU TODD , HUYETT LAUREN M. , DUMAIS BONNIE , LY TRANG T. , RIDDELL MICHAEL C. , 5 EXERCISE RESEARCH GROUP OMNIPOD 
Published: June 2024

Introduction and Objective: Assess Omnipod 5 System’s efficacy in managing glycemia during activity, comparing ‘Activity Feature’ initiated 30 (AF-30) or 60 min (AF-60) before exercise to automated delivery (Auto).
Methods: In this three-way crossover, 50 people with T1D (age 30±15 years, BMI 24.7±4.1 kg/m2, HbA1c 7.5±1.0%, and T1D duration 16±11 years) underwent a 70 min activity session (60 min exercise, 5 min rest at 20 and 45 min), 3hrs post-bolus, under each condition (Auto, AF-30, and AF-60). Pre-activity glucose was 90-200mg/dL. Up to 16g of carbs were provided if glucose was &lt;90mg/dL pre activity or &lt;70mg/dL during activity. Metrics were assessed using generalized estimating equations.
Results: Insulin delivery was decreased before and during activity for AF-30 and AF-60 vs Auto (p&lt;0.05, Table). During activity, AF-30 and AF-60 had smaller decreases in glucose, which was significant for Auto vs AF-30, p=0.03. Carb consumption during activity was higher for Auto vs AF-30 (p=0.02) and AF-60 (p=0.04). Time to hypo was delayed by 10 min (16% longer) in AF-30 and AF-60 relative to Auto.
Conclusion: Enabling Activity Feature 30 min before activity with Omnipod 5 may effectively mitigate glucose declines. Regardless, carb consumption may be necessary to minimize hypo risk during 60 min of exercise.

Disclosure
L.V. Turner: None. J.L. Sherr: Consultant; Medtronic. Advisory Panel; Medtronic, Insulet Corporation. Speaker's Bureau; Insulet Corporation. Advisory Panel; Vertex Pharmaceuticals Incorporated, MannKind Corporation, StartUp Health T1D Moonshot, Bigfoot Biomedical, Inc., Cecelia Health. Speaker's Bureau; Zealand Pharma A/S. D.P. Zaharieva: Research Support; Leona M. and Harry B. Helmsley Charitable Trust. Advisory Panel; Dexcom, Inc. Research Support; Insulet Corporation. Speaker's Bureau; Dexcom, Inc. Research Support; International Society for Pediatric and Adolescent Diabetes. Board Member; Juvenile Diabetes Research Foundation (JDRF). J.D. Baran: None. B.W. Bode: Research Support; Omnipod. Speaker's Bureau; Omnipod. Research Support; Medtronic. Advisory Panel; Medtronic. S.A. Brown: Research Support; Dexcom, Inc., Tandem Diabetes Care, Inc., Insulet Corporation, Tolerion, Roche Diagnostics. S. Bzdick: None. M. Church: None. D.W. Hansen: None. R.S. Kingman: None. L.M. Laffel: Consultant; Dexcom, Inc. Advisory Panel; Medscape, Medtronic, Vertex Pharmaceuticals Incorporated. Consultant; Novo Nordisk. Advisory Panel; Lilly Diabetes, Provention Bio, Inc., Sanofi-Aventis U.S., Janssen Pharmaceuticals, Inc., MannKind Corporation. V.N. Shah: Consultant; Dexcom, Inc., Insulet Corporation. Research Support; Insulet Corporation. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Sanofi, Medscape. Consultant; embecta, Tandem Diabetes Care, Inc. S.L. Stone: None. T. Vienneau: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation. L.M. Huyett: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation. B. Dumais: None. T.T. Ly: Employee; Insulet Corporation. M.C. Riddell: Consultant; Eli Lilly and Company. Speaker's Bureau; Novo Nordisk. Advisory Panel; Supersapiens. Consultant; Dexcom, Inc. Speaker's Bureau; Sanofi. Advisory Panel; Zealand Pharma A/S. Speaker's Bureau; Dexcom, Inc. Stock/Shareholder; Zucara Therapeutics.

Funding
This study was funded by Insulet Corporation.